Prospective II phase study on the evaluation of the efficacy of monotherapy with cetuximab as the first-line treatment for patients with metastatic colorectal cancer with wild-type KRas, NRas, and BRAF genes

Autor:	A.R. Venina Venina, G.A. Yanus Yanus, E.Sh. Kuligina, M.M. Kramchaninov Kramchaninov, N.M. Volkov Volkov, N.Kh. Abduloeva Abduloeva, K.V. Shelekhova Shelekhova, A.P. Sokolenko Sokolenko, A.V. Myslik Myslik, E.N. Imyanitov Imyanitov, St. Petersburg Clinical Scientific, V.A. Chubenko Chubenko, S.N. Aleksakhina Aleksakhina, A.G. Ievleva, A.O. Ivantsov Ivantsov, K.S. Kozyreva Kozyreva, E.V. Preobrazhenskaya, V.M. Moiseenko Moiseenko, N.V. Mityushkina Mityushkina, A.A. Kudryavtsev Kudryavtsev, F.V. Moiseenko Moiseenko, V.A. Khinshtein Khinshtein, A.S. Zhuravlev Zhuravlev
Rok vydání:	2018
Předmět:	Neuroblastoma RAS viral oncogene homolog Cetuximab business.industry Colorectal cancer Wild type medicine.disease_cause medicine.disease First line treatment Cancer research Medicine KRAS Braf genes business medicine.drug
Zdroj:	Pharmateca. :82-88
ISSN:	2414-9128
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::27bc77eac2ea2c929d41810f66670f8c https://doi.org/10.18565/pharmateca.2018.7.82-88 Zobrazit plný text záznamu